12 April 2017 - Closing arguments in the matter of the price of the patented medicine Soliris will be heard from Patented Medicine Prices Review Board staff, Alexion Pharmaceuticals and the intervenor, BIOTECanada, on Tuesday, April 18 and Wednesday, April 19, 2017.

The purpose of this hearing is to determine whether, under sections 83 and 85 of the Patent Act, Alexion, the pharmaceutical company that exercises patent rights for Soliris and sells the medicine in Canada, is selling or has sold Soliris in any market in Canada at a price that, in the opinion of the Hearing Panel of the Board, is or was excessive and if so, what order, if any, should be made.

Read Yahoo Finance article